# Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

> **NCT03098836** · PHASE2 · COMPLETED · sponsor: **Daniel George, MD** · enrollment: 93 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ARN-509
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03098836
- **Lead sponsor:** Daniel George, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-10
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03098836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03098836, "Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03098836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*